Temitope Fowora
Family · Towson, MDNPI 1972998086
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $13,627 of the $17,220 with a category attached, or 79.1%. 42 manufacturers reported payments, led by Boehringer Ingelheim at 24.1% of the total. Reporting peaked in 2024 at $7,093 and has fallen 53.9% since, to $3,270 in 2025. Among family clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 628 payments — averaging $27.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$4K
- AstraZeneca$2K
- GSK$2K
- Jazz Pharmaceuticals Inc.$2K
- Harmony Biosciences LLC$847
- Axsome Therapeutics, Inc.$728
- plus $6K from 36 others
What the payments were for
- Consulting fees$2,49014%
- Travel & lodging$7564%
- Food & beverage$13,62779%
- Education$3472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,220 in reported general payments places this provider in the 95th percentile of 2,843 family providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 54 | $713,000 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 314 | $325,827 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 119 | $113,508 |
| Dupixent PenDupilumab | 19 | $72,769 |
| Fasenra PenBenralizumab | 12 | $68,800 |
| XolairOmalizumab | 12 | $67,803 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 11 | $53,326 |
| Breo ElliptaFluticasone/Vilanterol | 69 | $42,282 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 48 | $32,511 |
| Incruse ElliptaUmeclidinium Bromide | 44 | $20,100 |
| Spiriva RespimatTiotropium Bromide | 21 | $18,632 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 19 | $17,643 |
| Fluticasone Propionate HfaFluticasone Propionate | 34 | $13,516 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $9,968 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $9,427 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $4,143 | $749,27594 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,948 | $429,463501 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Airsupra | $1,971 | $128,529153 claims |
| Grifols USA, LLCProlastin C | $364 | $53,32611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,843 family providers in Maryland.
Other family in Towson
- Erika HoffmanPotomac$226K
- Caroline MansySalisbury$106K
- Hazel Jones-ParkerBaltimore$96K
- Brittany WilsonBaltimore$88K
- Ariana ChaoLutherville$85K
- Meredith SagalHunt Valley$82K
- Sharon Dudley-BrownBel Air$67K
- Joy MaulikSalisbury$47K
- Kristin AttiogbeChevy Chase$42K
- Sametta SanyaoluFulton$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.